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The condilions and efficacy of transfection of vascular cells in primary culture using DEAE-dextran, calcium phosphate and lipofeetin have been 
investigated using chloramphcnicol acetyltransfcrase and luciferasc as rcportcr genes. Subsqucmly factor VI11 was expressed in endothelial and 
smooth muscle cells. Both reporter genes could be expressed after transkction of umbilical vein endothelial cells, umbilical artery smooth muscle 
cells and fibroblasts. The expression of both reporter genes in endothelial and smooth muscle cells was highest using lipofectin. After tmnsfection 
of smooth muscle cells with both full-length and mutant factor VIII genes, factor VIII activity and antigen were secreted into the culture medium, 
the secretion remaining stable to serial cell passage. The secretion of facto: VIII from transkcted smooth muscle cells was confirmed by the 
immunoprecipitation of [“Slmcthionine labelled protein. Endothclial cells also were successfully trsnsfected with the mutant factor VIII gene. 
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1. INTRODUCTION 
The continued flow of blood through the vasculature 
and delivery of nutrients to metabolizing tissues de- 
pends on an intact endothelium and the vascular tone. 
With ageing and atherosclerosis these properties of the 
arterial tree are impaired: blood flow may be restricted 
and limbs and organs put at risk. The clinical approach 
is to offer bypass surgery or endovascular intervention 
for critical ischemia. The success of these approaches is 
limited either by thrombosis or the response of the ves- 
sel wall to intervention and this has not been improved 
by pharmacological manipulation. The rapid advances 
in molecular and cellular biology have provided the 
basis for the suggestion that gene as;amentation could 
underlay new advances in the treatment of cardiovascu- 
lar disease [1,2]. Equally the vasculature could be used 
to augment deficiencies of plasma components by gene 
therapy. Several recent reports have demonstrated the 
feasibility of these approaches. Retroviral vectors and 
cationic liposomes have been used to introduce the /?- 
galactosidase gene into arteries ubject o balloon cath- 
eter angioplasty and genetically modified endothelial 
cells have been used to coat the surface of prosthetic 
grafts [3-51. 
cells. Here we have compared the use of three different 
non-infectious procedures for inserting and expressing 
‘foreign DNA’ in primary cultures of endothelial, 
smooth muscle cells and fibroblasts using chloram- 
phenicol acetyltransferase (CAT) and lucifcrase as re- 
porter genes. Using the most successful conditions we 
have then attempted to insert and express the much 
larger gene of a protein with complex post-translational 
modifications, factor VIII, in endothelial and smooth 
muscle cells. 
2. MATERIALS AND METHODS 
2.1, Cell cukure 
Endothelial cells wcrc isolated from human umbilical veins, cul- 
tured and identified as previously described [6.7]. Smooth muscie cells 
were isolated from explants of human umbilical artery and cultured 
using the same conditions as for endothelial cells. These cells were 
identified with an antib&y specific for smooth muscle cell aetin. 
Fibroblasts were isolated from the adventitia of human umbilical 
arteries and subcultured using the same me& and conditions as 
endothelial cells. Transfection experiments were conducti using cn- 
dothelial and smooth muscle cells at second or third passage and 
fibroblasts at passage 5-8. 
2.2. Transjiecrion studies 
Most attention appears to have been given to the 
infectious methods for genetic modification of vascular 
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All cells were transfected at 70-80% confluence. Cells were trans- 
fected using DEAE-dextran using 10 pug DNA for each 10 cm’ dish 
[S]. After 2-2.5 h thecells were shocked by the addition ofchloroquine 
to a final concentration of 80 pg/ml for smooth muscle cells and 
libroblasts but a final concentration of 40 j&/ml for cndothelial cells. 
Calcium phosphate transfections wcrc conducted h Iscoves medium, 
supplemented with 20% pooled humam) serum, for 4 h using !O ~6 
DNA for each 10 cm’ dish [9]. Chloroquinc MS added to the same 
final concentration. as for DEAE-dextrdn trdnsfections, after 2 h. 
Lipofections were performed in RPMI- 1640 supplcmezt.‘.ed with 2 mM 
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glutamine. penicillin (100 U/ml)and streptomycin (lOO~g/ml). accord- 
ing to the manufacturers instructions (GIBW-BRL). On the day abler 
transfection cells were washed twice with RPMI.1640 and replenished 
with fresh medium (2 ml/10 cm? dish). Cells were harvested with 0,2S% 
trypsin 2-6days after transfection. Trypsin was subsequently inhlbited 
with soyabean trypsin inhibitor (IO mgml). 
2.3. Plaanid DNA 
The different cDNAs were all constructed in the pSVL series of 
plasmids and purified through two CsCl grddienls 191. The RSV pro. 
moter controlled luciferase and chloramphenicol acetyltransferase 
(CAT) plasmids were a gift from Dr. A.J. van Zonneveld [lo], Two 
factor VIII plasmids were used. both with the cDNA fused to the RSV 
promoter: a full-length 7,436 bp insert (FL) and 2 5,351 bp insert, 
coding for factor VIII with deletion of amino acids 867--1,562 of the 
B domain, factor VIII-d (868-1562) [I I]. 
2.4. En:yrtte assays 
Chloramphmicol acetyltransferase and luciferase were assayed in 
cell extracts as previously described [12,13]. Their specific activity was 
calculated abler determination of the protein content of cell extracts 
using the dye binding assay described by Bradlbrd [ 141. Factor VIII 
activity was determined spectrophotomelrically using a chromogenic 
substrate and purified bovine coagulation factors (Coatest Factor 
VIlI, KabiVitrum, Stockholm, Sweden). Factor VIII activity is ex- 
pressed in U/ml where I U/ml represents he concentration of factor 
VII1 in pooled normal human plasma (about 100 ndml). Factor VIII 
antigen was measured by an enzyme-linked immunoabsorbant assay, 
as previously described [IS], 
2.5. Metubolic lab&q with fJsS]trrc&onine und Ittwruloprecipira- 
riot8 
AfLcr transfection and medium changeendothelial and smooth mus- 
cle cells were maintained for 72 h before washing with RPMI-1640 and 
transfer to serum-free RPM1 medium lacking methionine for a period 
of 1 .S h. The methionine free medium was then removed and replaced 
with the same medium supplelrrented with [?5]methionine (IO@Xml). 
Cells were maintained in the [“Slmethionine medium for 4 h before 
the cells were washed twice with RPMI-1640 and replenished with full 
medium. After I5 h the culture medium was assayed for factor VIII 
activity and if appropriately positive the metabolic labolling was termi- 
nated after I8 h, The labelled media were centrifuged for IO min at 
8,000 x g to remove cells and debris and concentrated lysls buffer 
added to achieve Rnal concentrations of 1% Nonidet P40,O. I M NaCI, 
20 mM TrisiCl. 4 mM EDTA at pH 7.5. Cells were lysed by addition 
of this same butrer and freezing at -70°C. The lysis buffer was supple. 
mented with a cocktail of protease inhibitors: I mM phenylmcth- 
ylsulphonyl fluoride, 0.02 m&ml soyabean trypsin inhibitor, 10 mM 
benzamidine, 5mM N-ethylmaleimide, Pre-clearance was achieved by 
successive incubation with gelatin&pharose at 37°C for 2 h, passage 
through columns (0.5 ml) of protein A-Sepharose and mouse I& 
protein A-Sepharose, prior to specilic immobilization of labclled fac- 
tor VIII by incubation (16 h, 4OC) with a mixture of monoclonal 
antibodies (CLB-Cag 9, CLB-Cag 117 and CLB-CagA) coupled to 
protein A-Sepharose [IS]. After extensive washing (3 times with lysis 
buffer, twice with 0.25 M CaCI> containing25 mM Tris/CI, pK 7.8 and 
1% Nonidet NP40, once with 1 M NaCl containing 25 mM Tris/Cl pH 
7.8 and the final wash with 0.1 M NaCl containing 25 mM Tris/CI pH 
7.8) immune complexes were removed from the Sepharose by boiling 
in 1% SDS for 5 min and analyzed by SDS/polyacrylamide gel electro- 
phoresis under reducing conditions followed by autoradiography. 
3. RESULTS 
The efiiciency of transfection varies greatly according 
to the conditions used, such conditions including the 
length of transfection, concentration of DNA, concen- 
tration of chloroquine used to shock cells, aad cell den- 
sity. Three methods of transfection, DEAE-dextran, 
calcium phosphate and lipofectin, were compared using 
cells at 70% confluence, 10 pg DNA with an RSV pro- 
moter/10 cm2 well and a 4 h exposure to plasmid DNA, 
The expression of luciferase was highest in smooth mus- 
cle cells and least in fibroblasts, irrespective of the mode 
of transfection (Table I). The expression of chloram- 
phenicol acetyl transferase was similar to luciferase 
(data not shown). After DEAE-dextran-mediated trans- 
fection, luciferase activity was maximal at 3 days and 
had reduced to background for all 3 cell types after 7 
days. In contrast lipofectin-mediated luciferase activity 
remained stable between 3 and 14 days and was stable 
to at least one cell passage (1:2 split) in all 3 cell types. 
After transfection of smooth muscle cells with factor 
VIII genes with lipofectin, factor VIII activity and fac- 
tor VIII antigen could be detected in the culture medium 
(Table II). Three days after transfection with factor VIII 
4(865-1562) construct he mean activity of the culture 
medium was 3.5 + 1.8 mu/ml (~2 = 8) with a concentra- 
tion of 2.5 k 1.2 mu/ml being detected by ELISA. After 
transfection with full-length factor VIII cDNA the 
mean activity of the culture medium was only 1.0 f 0.8 
mu/ml 72 h after transfection but rose to 1.8 k 1.2 mU/ 
ml 6 days after transfection (n = 9); antigen was not 
detectable 3 days after transfection but was detected 6 
days after transfection (1.8 k 1.1 mu/ml). The amount 
of factor VIII secreted into the culture medium could 
be increased by process of differential adhesion. Brief 
trypsinization (2 min, 37OC) removes a population of 
cells which, after replating and growth, secreted very 
little factor VIII activity into the culture medium. After 
growth of the residual cells to confluence the factor 
VIII-&868-1562) activity in the medium increased 2-3- 
fold to 8.5 f 2.8 mu/ml or antigen concentration to 
5.5 -1- 1.7 mu/ml. The stability of factor VIII (4695) 
gene expression by transfected smooth muscle cells was 
investigated by serial passage of cells after lipofection. 
All the cells were detached by trypsinization (7 min, 
37OC), subcultured at half density and grown up to 
Table I 
Comparison of non-inrectious methods of transfection in primary 
vascular cells 
Cell Luciferase (ng/mg protein) after transfection with 
DEAE dextran Calcium Lipofectin 
phosphate 
Endotheliat 8.9 r I.0 28.0 + 1.7 86.7 2 16.7 
Smooth muscle 8.2 r 0.3 18.9 + 7.7 65.3 f I I.4 
Fibroblast I .4 f 0.5 11.8 f 3.0 5.6 f 0.5 
The cells were exposed to IO pug RSV luciferase DNA for 4 h using 
DEAE-dextmn, calcium phosphate or lipofectin as the carrier. Cells 
were harvested 72 h following the termination of transfection, lysed 
by freeze-thaw cycles and luciferase, and protein was determined in 
the cell extracts. The results are given as the mean P S.D. of 6 
experiments. 
174 
Volume 303, number 2,3 FEBS LETTERS June 1992 
Table II 
Lipofectin-mediated transfection of smooth muscle cells with factor VIII c%prcssion plasmids 
Cell passage Factor VIII cDNA Time after ttansfection Activity mUmI + SD. Antigen mU/ml + SD. II 
(days) 
: full fu l length I S 6 3 1.0 1.8 + ?r0.8 I.2 1.8& nd 1.1 6 5 
3 4(868- 1562) 3 3.5 2r I.8 2.5 + 1.2 8 
3 4(868-1562) 6 4.0 2 0.9 3.0 * 0.7 4 
3 4(868-1562) 7 8.5 + 2.0 7.5 + 2.0 2’ 
4 4(868-l 562) 9 I I.2 2 3.6 15.5 +- 5.2 (4 flasks) 
S 6(868-1562) II 8.2 + 1.8 14.1 + 3.3 (8 flasks) 
6 4(868-1562) I5 6.7 + I.1 13.0 f 2.2 (8 flasks) 
7 4(868-l 562) I8 7.8 + 0.8 13.2 * 2.3 (8 flasks) 
8 4(868-l 562) 22 8,l ? 0.9 9.1 + 2.4 (8 flasks) 
*The experiment was repeated twice, the smooth muscle cells being derived from two separate transfections of smooth muscle cells in their third 
passage. A maximum of four Rasks (80 cm?) were retuincd after each successive passage. each flask contained -5 x 10’ cells. nd, not detectable. 
confluence. Secretion of factor VIII activity and antigen weak, broad band was observed at high molecular 
was stable through 5 passages (Table II). Immunofluo- weight, 320 kDa (Fig. 2). No specific bands were ob- 
rescent microscopy demonstrated intracellular localiza- served after immunoprecipitation ofthe culture medium 
tion, probably associated with Golgi membranes, of of smooth muscle cells similarly transfected with chlo- 
factor VIII protein in a few of these cells (Fig. 1). ramphcnicol acetyltransferase plasmid. 
The expression of factor VIII and factor VIII-,4(868- 
1562) by transfected smooth muscle cells was confirmed 
by metabolic labelling of the proteins with [35S]methion- 
ine. From smooth muscle cells transfected with the mu- 
tant factor VIII-d(868-1562) plasmid-lipofectin micelles 
a strong, sharp band of about 190 kDa was visible after 
resolution on 6% acrylamide gels and autoradiography 
(Fig. 2). For smooth muscle cells transfected with full- 
length factor VIII plasmid-lipofectin micelles only a 
Extensive modification of the transfection conditions 
was necessary before any secretion of factor VIII activ- 
ity and antigen could be detected. Endothelial cellst in 
25 cm2 flasks, were exposed to micelles of DNA and 
lipofectin (10 lug DNA, 35 yg lipofectin in 100~1 of 
water) in serum free medium for 2.5 h before the addi- 
tion of Ultroser G to a final concentration of 1%. After 
15 h, the cells were washed and fed with complete me- 
Fig. I. Smooth muscle cells transfccted with lipofectin and the factor WI deletion mutant. The cells were passaged three times after tranefection, 
fixed and reacted with a polyclonal antibody IO factor VIII raised in rabbits, followed by a fluorescein conjugated second antibody. A few cells 
show bright staining of intracellular organclles. possibly Golgi membranes; final magnification x315. Cells transfected with chloramphenicol 
acetyltransferase do not show these structures when similarly stained. 
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1 2 3 
Fig. 2. Immunoprccipitation a d resolution of metabolically labellcd 
factor VIII sccrercd by tranvfected smooth muscle cells. Smooth mus- 
cle cells were transfccted with chloramphcnicol acetyltransferase, the 
factor VIII deletion mutant, factor VIII~&368-1562) and full-length 
factor VIII using lipofectin. The cells were labelled with [“Slmethion- 
ine, factor VIII immunoprecipitated from the culture medium amd 
separated on polyacrylamide gels, as described in the text. The autora- 
diograph shows the r sults from the factor WI de!etion mutant rans- 
fected cells in lane I, from cells transfected with full-length factor VIII 
in lane 2 and from chloramphenicol acetyltransferase transfccted cells 
in lane 3, The molecular weight calibration is shown on the right hand 
side. 
dium: about 10-l 5% of cells remained. After 7 days the 
cells had again reached confluence and factor VIII ac- 
tivity (l-2 mu/ml) could be detected in the medium of 
cells transfected with the 4(868-1562) plasmid. After 
detaching and discarding about half the cells by brief 
trypsinization (2 min, 22OC) the remaining cells were 
allowed to again grow to confluence and the accumula- 
tion of factor VIII in the medium increased to 4-5 mU/ 
ml and antigen could be detected in the medium (3 
mu/ml). Factor VIII secretion could not be detected 
from endothelial cells similarly transfected with CAT or 
full-length factor VIII plasmids. 
4. DISCUSSION 
Chloramphenicol acetyltransferase and luciferase are 
small intracellular proteins whose genes have been used 
widely in rransfection experiments to report both the 
efficiency of transfection and to study the activity of 
promoters fused to these reporter genes: usually, for 
such studies established cell lines are used. Here experi- 
ments with reporter genes clearly demonstrated that 
cultured primary cells of the normal vasculature, in- 
cluding endothelial, smooth muscle cells and fibro- 
blasts, also could take up plasmid DNA and transiently 
express luciferase and/or chloramphenicol acetyltrans- 
ferase. In additon, the present study demonstrates that 
the factor VIII gene, a gene that both in a transient 
manner and in established cell lines is difficult to ex- 
press, iu readiiy expressed insmooth musde cells, partic- 
ularly when lipofectin was the carrier of DNA into the 
cells [16,17]. 
The procedures for lipofection appear to alter the 
interactions of cultured cells with their subtratum. Ir- 
respective of the expression plasmid used, endothelial, 
smooth muscle cells and fibroblasts resisted complete 
detachment under the normal conditions of trypsin de- 
tachment. After lipofection, endothelial cells also be- 
came resistant o detachment with EGTA, We have no 
evidence concerning the mechanism of this altered cell- 
substratum adhesion. The transfection techniques eval- 
uated here provided a rationale to examine the expres- 
sion of genes that may modulate the haemostatic poten- 
tial of the vasculature in a transient manner, a potential 
application of the present study. Lipofection became the 
method of choice to attempt o introduce the factor VIII 
gene, and a mutant thereof, in endothelial and smooth 
muscle cells. 
Factor VIII, a protein that is deficient in haemophilia 
A and von Willebrand’s disease, is a large molecule, the 
cDNA encodes a single chain of 2,332 amino acids 
which can be divided into six domains [l&19]. The larg- 
est of these, the B-domain occupies over 900 amino 
acids in the middle of the polypeptide chain and con- 
tains most of the potential glycosylation sites [16,19,20]. 
The construction and expression of deletion mutants 
has indicated that this domain is not necessary to the 
function of factor VIII [21]. The reduction in length of 
the cDNA encoding such deletion mutants appears to 
be advantageous for the expression of factor VIII activ- 
ity after transfection of mammalian cell lines [ 16,17,2 11. 
For these reasons we attempted the transfection of vas- 
cular cells with both expression plasmids containing the 
full-length factor VIII cDNA and a mutant with 695 
amino acids of the B-domain deleted, factor VIII- 
4(868-l 562) [1 I]. We too observed increased expression 
of factor VIII activity and/or antigen after transfection 
of muscle cells with this deletion mutant as compared 
with full-length factor VIII plasmids. It has become 
accepted that factor VIII is difficult to express effi- 
ciently in mammalian cell lines [ 161. Again we made 
similar observations after iipofection of smooth muscle 
cells, these cells expressing the reporter genes 1-2 orders 
of magnitude more efficiently than the deletion mutant: 
maximum expression of factor VIII-d(868-1562) pro- 
tein about 0.5 ng/lO cm? well compared with luciferase, 
about 20 n&l0 cm2 well. 
Lipofectin permits the stable integration and expres- 
sion of foreign genes in mammalian c-ells and may ex- 
plain why the factor VIII secretion from successfully 
transfected smooth muscle cells is stable through several 
cell passages (Table I). Factor VIII protein could be 
immunolocalized to cytoplasmic organelles, probably 
the Golgi, in a few cells (Fig. 1). This would be appro- 
priate since the Golgi is the site of sulphation and termi- 
nal glycosylation of secreted proteins; the deletion mu- 
tant factor VIII-C(86S-I 562) contains both sulphaGor. 
and glyccsylation sites [16,17,19]. This mutant and 
probably full-length factor VIII appear to be secreted 
as single chain proteins, apparent molecular weights I90 
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kDa and 320 kDa respectively (Fig. 2). A molecular 
weight of 330 kDs has been reported previously for the 
mature, glycosylated full-length factor VIII [22]: the 
considerably smaller size of the mutant protein proba- 
bly results from the deletion of most of the glycosylation 
sites. The expression of both these forms of factor VIII 
as single chains might appear surprising in view of the 
complex proteolytic processing observed in factor VIII 
preparations from human plasma, nevertheless previ- 
ous expression studies in COS cells have also demon- 
strated the secretion of factor VIII as a single chain [17]. 
A potential application of the present study is the 
transfection of genes which modulate haemostasis at the 
blood-vessel interface. It is evident that primary vascu- 
lar cells readily can be transfected by small reporter 
genes, without using retroviral vectors or other infec- 
tious techniques. Significant expression of such reporter 
genes by endothelial and smooth muscle cells can be 
obtained after even brief lipofection and provides for 
stable expression of augmented genes. The potential of 
this technique to gene augmentation in cardiovascular 
disease may be limited by the difficulties of augmenting 
cells with the larger genes of more complex proteins or 
the specific biology of each particular vascular cell. 
Much remains to be learnt before such technologies find 
application in vascular medicine. 
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